Document Detail


Folic acid supplementation improves erythropoietin response.
MedLine Citation:
PMID:  8587618     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Therapy with recombinant human erythropoietin (rhEPO) has become most valuable for the treatment of renal anemia in patients with various chronic renal diseases. For the first time this study presents data showing that rhEPO affects the metabolism of folic acid. There were 13 patients enrolled; they suffered from different chronic renal diseases and showed an impaired responsiveness to rhEPO therapy. Before starting rhEPO therapy the mean corpuscular volume of erythrocytes (MCV) was measured; MCV was 90.4 fl. During rhEPO therapy the MCV increased significantly by 14.8 fl (p < 0.05). The developing macrocytic anemia was overcome when folic acid was administered additionally for a mean period of 3.14 +/- 3 months. Hematocrit (Hct) also responded accordingly. Whereas Hct did not increase adequately during the exclusive treatment with rhEPO, an increase in Hct from 23 +/- 3.3 to 30 +/- 4.2% (p < 0.01) was observed after the addition of folic acid. These results are rather remarkable as folic acid serum levels were clearly within the normal range during the whole study period. So it can be concluded that rhEPO therapy results in an increased demand for folic acid. Even if serum concentrations are within the normal range, the administration of folic acid will enhance the effectiveness of rhEPO therapy so that the rhEPO dosage can be reduced.
Authors:
W Pronai; M Riegler-Keil; K Silberbauer; F Stockenhuber
Related Documents :
10958818 - Conversion of 5-formyltetrahydrofolic acid to 5-methyltetrahydrofolic acid is unimpaire...
17544768 - Efficacy of folic acid supplementation in stroke prevention: a meta-analysis.
2179438 - St cadoc and the healing of the deaf.
18693708 - The self-assembly of metaboric acid molecules into bowls, balls and sheets.
16885258 - Production of a heterologous nonheme catalase by lactobacillus casei: an efficient tool...
18808128 - Studies on the synthesis of durhamycin a: stereoselective synthesis of a model aglycone.
Publication Detail:
Type:  Clinical Trial; Journal Article    
Journal Detail:
Title:  Nephron     Volume:  71     ISSN:  0028-2766     ISO Abbreviation:  Nephron     Publication Date:  1995  
Date Detail:
Created Date:  1996-03-28     Completed Date:  1996-03-28     Revised Date:  2004-11-17    
Medline Journal Info:
Nlm Unique ID:  0331777     Medline TA:  Nephron     Country:  SWITZERLAND    
Other Details:
Languages:  eng     Pagination:  395-400     Citation Subset:  IM    
Affiliation:
Department of Internal Medicine, Krankenhaus der Barmherzigen Brüder, Eisenstadt, Austria.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Aged
Anemia / drug therapy*,  etiology,  metabolism
Diet
Drug Therapy, Combination
Erythropoietin / adverse effects,  therapeutic use*
Female
Folic Acid / blood,  therapeutic use*
Hematinics / blood,  therapeutic use*
Hematocrit
Humans
Kidney Failure, Chronic / complications*
Male
Middle Aged
Recombinant Proteins / adverse effects,  therapeutic use
Chemical
Reg. No./Substance:
0/Hematinics; 0/Recombinant Proteins; 11096-26-7/Erythropoietin; 59-30-3/Folic Acid
Comments/Corrections
Comment In:
Nephron. 1999;81(3):353   [PMID:  10050095 ]
Nephron. 1998;78(1):115   [PMID:  9453413 ]
Nephron. 1997;76(1):119   [PMID:  9171312 ]

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Nephrosis in childhood.
Next Document:  Studies concerning the optimization of dialysate consumption.